genprowebdirectory
Facebook
Linkedin
RSS
Twitter
Youtube
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Facebook
Linkedin
RSS
Twitter
Youtube
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2017
Nephropathy
Drug Discovery
Omeros’ Lead mAb Granted Breakthrough Therapy Designation for IgA Nephropathy
Industry News
Anthera Candidate Sollpura Fails Phase III Trial
Industry News
NephroGenex to “Pause” Pyridorin Development, Restructure, and Seek Strategic Alternatives
News
Lilly, Incyte Report Successful First Phase III Trial for Baricitinib
News
AstraZeneca, MTPC Partner to Validate Diabetic Nephropathy Targets
News
AstraZeneca, Max Planck Launch CVMD Collaboration
Cancer
EC Conditionally Sanctions Lymphoma Treatment
Industry News
Genkyotex Raises $26M for Diabetic Nephropathy Drug
Industry News
Pharmlink Raises SEK35M for Late-Stage Development of Nefecon and Busulipo
Drug Discovery
Pharmalink Licenses Archimedes’ Targit Enteric Delivery Technology
1
2
Page 1 of 2
Scroll Up
Scroll Up
